Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

Philip A Poole-Wilson; Karl Swedberg; John GF Cleland; Andrea Di Lenarda; Peter Hanrath; Michel Komajda; Jacobus Lubsen; Beatrix Lutiger; Marco Metra; Willem J Remme; Christian Torp-Pedersen; Armin Scherhag; Allan Skene

doi:10.1016/s0140-6736(03)13800-7

journal article Jul 01, 2003

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

Philip A Poole-Wilson Karl Swedberg John GF Cleland Andrea Di Lenarda Peter Hanrath Michel Komajda Jacobus Lubsen Beatrix Lutiger Marco Metra

Willem J Remme Christian Torp-Pedersen

Armin Scherhag Allan Skene

The Lancet Vol. 362 No. 9377 pp. 7-13 · Elsevier BV

View at Publisher Save 10.1016/s0140-6736(03)13800-7

Topics

No keywords indexed for this article. Browse by subject →

References

29

[1]

Cowie "The epidemiology of heart failure" Eur Heart J (1997) 10.1093/oxfordjournals.eurheartj.a015223

[2]

Remme "Guidelines for the diagnosis and treatment of chronic heart failure" Eur Heart J (2001) 10.1053/euhj.2001.2783

[3]

Garg "Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: collaborative Group on ACE Inhibitor Trials" JAMA (1995) 10.1001/jama.1995.03520420066040

[4]

Packer "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure" N Engl J Med (1996) 10.1056/nejm199605233342101

[5]

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

The Lancet 1999 10.1016/s0140-6736(98)11181-9

[6]

"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)" Lancet (1999) 10.1016/s0140-6736(99)04440-2

[7]

Packer "Effect of carvedilol on survival in severe chronic heart failure" N Engl J Med (2001) 10.1056/nejm200105313442201

[8]

Shibata "Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure" Eur J Heart Fail (2001) 10.1016/s1388-9842(01)00144-1

[9]

Hjalmarson "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group" JAMA (2000) 10.1001/jama.283.10.1295

[10]

Bolger

[11]

"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease" Lancet (1997) 10.1016/s0140-6736(97)80008-6

[12]

Gilbert "Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart" Circulation (1996) 10.1161/01.cir.94.11.2817

[13]

"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure" N Engl J Med (2001) 10.1056/nejm200105313442202

[14]

Packer "Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis" Am Heart J (2001) 10.1067/mhj.2001.115584

[15]

Di Lenarda "Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group" J Am Coll Cardiol (1999) 10.1016/s0735-1097(99)00134-5

[16]

Metra "Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol" Circulation (2000) 10.1161/01.cir.102.5.546

[17]

Sanderson "Beta-blockade in heart failure: a comparison of carvedilol with metoprolol" J Am Coll Cardiol (1999) 10.1016/s0735-1097(99)00367-8

[18]

Jacob "Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study" J Hypertens (1996) 10.1097/00004872-199604000-00012

[19]

Yue "Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger" J Pharmacol Exp Ther (1992)

[20]

Rossig "Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol" J Am Coll Cardiol (2000) 10.1016/s0735-1097(00)01002-0

[21]

Poole-Wilson "Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET" Eur J Heart Fail (2002) 10.1016/s1388-9842(02)00025-9

[22]

Peto "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design" Br J Cancer (1976) 10.1038/bjc.1976.220

[23]

Lubsen "Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained" Lancet (2000) 10.1016/s0140-6736(00)03215-3

[24]

Composite Outcomes in Randomized Trials

Nick Freemantle, Melanie Calvert, John Wood et al.

JAMA 2003 10.1001/jama.289.19.2554

[25]

Waagstein "Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy" Br Heart J (1975) 10.1136/hrt.37.10.1022

[26]

Waagstein "Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy" Lancet (1993) 10.1016/0140-6736(93)92930-r

[27]

Sandberg "Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets" Eur J Clin Pharmacol (1988) 10.1007/bf00578406

[28]

Wikstrand "Dose of Metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF)" J Am Coll Cardiol (2002) 10.1016/s0735-1097(02)01970-8

[29]

Lechat "Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial" Circulation (2001) 10.1161/01.cir.103.10.1428

Cited By

1,444

Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure

Ross T. Campbell, Gage P. Willox · 2016

Circulation: Heart Failure

2013 ACCF/AHA Guideline for the Management of Heart Failure

Clyde W. Yancy, Mariell Jessup · 2013

Journal of the American College of...

Metrics

1,444

Citations

29

References

Details

Published: Jul 01, 2003
Vol/Issue: 362(9377)
Pages: 7-13
License: View

Authors

P

Philip A Poole-Wilson

K

Karl Swedberg

From the Brigham and Women’s Hospital, Boston, MA (E.F.L., B.L.C., J.L., A.S.D., S.D.S.); BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Novartis, East Hanover, NJ (M.P.L., V.C.S.); Institut de Cardiologie de Montreal, Université de Montreal, Canada (J.L.R.); Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC ...

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, University of Brescia , Brescia ,

W

Willem J Remme

C

Christian Torp-Pedersen

Copenhagen University Hospital Gentofte, Copenhagen, Denmark

Cite This Article

Philip A Poole-Wilson, Karl Swedberg, John GF Cleland, et al. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet, 362(9377), 7-13. https://doi.org/10.1016/s0140-6736(03)13800-7

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

You May Also Like